PMID- 36187126
OWN - NLM
STAT- MEDLINE
DCOM- 20221004
LR  - 20221207
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Association between lncRNAs in plasma exosomes and diabetic retinopathy.
PG  - 987488
LID - 10.3389/fendo.2022.987488 [doi]
LID - 987488
AB  - BACKGROUND: Long noncoding RNA (lncRNA) in plasma exosomes is a potential 
      non-invasive diagnostic biomarker for diabetic retinopathy (DR). However, the 
      changes in plasma exosomal lncRNAs and diagnostic relevance in patients with DR 
      patients remain unclear. METHODS: A case-control study with type 2 diabetes 
      mellitus (T2DM) and patients with comorbid DR were enrolled, and their clinical 
      information and blood samples were collected. Plasma exosomes were extracted, and 
      the relative expression levels of representative differentially expressed 
      exosomal lncRNAs were determined. A logistic regression model was used to analyze 
      the relationships of DR with relative lncRNA expression and DR-related factors, 
      and receiver operating characteristic (ROC) curve analysis was used to evaluate 
      the value of exosomal lncRNAs for DR diagnosis. RESULTS: Sixty-two patients with 
      T2DM and sixty-two patients with DR were matched by age, sex, and disease 
      duration. The fasting blood glucose concentration, glycosylated hemoglobin level 
      (HbA(1c)), and relative expression of the plasma exosomal lncRNA DLX6-AS1 were 
      significantly higher in the DR group than in the T2DM group, whereas the 2-h 
      C-peptide concentration and relative expression of the lncRNAs PRINS and 
      FAM190A-3 were lower in the DR group. After adjusting for relevant confounders, 
      the fasting blood glucose concentration, HbA(1c) level, 2-h C-peptide 
      concentration, and relative expression of lncRNA DLX6-AS1, PRINS, and FAM190A-3 
      were found to be associated with DR. Both DLX6-AS1 [area under the curve (AUC): 
      0.658 (0.562-0.754)], PRINS [AUC: 0.798 (0.722-0.873)], and FAM190A-3 [AUC: 0.603 
      (0.503-0.702)] expression had predictive value for DR diagnosis. The combination 
      of DLX6-AS1 and PRINS yielded an AUC of 0.813 (0.740-0.886). In males, the 
      combination of DLX6-AS1 and PRINS yielded an AUC of 0.860 (0.780-0.940). 
      CONCLUSION: The fasting blood glucose concentration, HbA(1c) level, and exosomal 
      DLX6-AS1 expression were identified as risk factors for DR, whereas the 2-h 
      C-peptide concentration and exosomal PRINS and FAM190A-3 were identified as 
      protective against DR. The combination of exosomal DLX6-AS1 and PRINS had good 
      diagnostic value for DR in the general population and males. More attention 
      should be paid to the role of exosomal PRINS expression as a predictive and 
      diagnostic DR biomarker in females.
CI  - Copyright (c) 2022 Ye, Li, Shao, Xu, Li, Yan, Huang and Zhao.
FAU - Ye, Qingqing
AU  - Ye Q
AD  - Clinical Laboratory, Beilun District People's Hospital, Ningbo, China.
FAU - Li, Lian
AU  - Li L
AD  - Department of Prevention and Control, Ningbo Kangning Hospital, Ningbo, China.
FAU - Shao, Zhoujie
AU  - Shao Z
AD  - Clinical Laboratory, Beilun District People's Hospital, Ningbo, China.
FAU - Xu, Miao
AU  - Xu M
AD  - Department of Endocrinology, Ningbo First hospital, Ningbo, China.
FAU - Li, Li
AU  - Li L
AD  - Department of Endocrinology, Ningbo First hospital, Ningbo, China.
FAU - Yan, Qianqian
AU  - Yan Q
AD  - Department of Global Health, Ningbo Institute of Life and Health Industry, 
      University of Chinese Academy of Sciences, Ningbo, China.
FAU - Huang, Bin
AU  - Huang B
AD  - Department of Emergency Medicine, Beilun District People's Hospital, Ningbo, 
      China.
FAU - Zhao, Tian
AU  - Zhao T
AD  - Department of Global Health, Ningbo Institute of Life and Health Industry, 
      University of Chinese Academy of Sciences, Ningbo, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220914
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Biomarkers
MH  - Blood Glucose
MH  - C-Peptide
MH  - Case-Control Studies
MH  - *Diabetes Mellitus, Type 2/diagnosis/genetics
MH  - *Diabetic Retinopathy/diagnosis/genetics
MH  - *Exosomes/genetics/metabolism
MH  - Female
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Male
MH  - *RNA, Long Noncoding/genetics
PMC - PMC9519175
OTO - NOTNLM
OT  - case-control study
OT  - diabetic retinopathy
OT  - exosome
OT  - lncRNA
OT  - type 2 diabetes mellitus
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/10/04 06:00
MHDA- 2022/10/05 06:00
PMCR- 2022/01/01
CRDT- 2022/10/03 04:46
PHST- 2022/07/06 00:00 [received]
PHST- 2022/08/12 00:00 [accepted]
PHST- 2022/10/03 04:46 [entrez]
PHST- 2022/10/04 06:00 [pubmed]
PHST- 2022/10/05 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.987488 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Sep 14;13:987488. doi: 
      10.3389/fendo.2022.987488. eCollection 2022.